Pagan FL - Search Results

1

Improving outcomes through early diagnosis of Parkinson's disease.

Pagan FL. Pagan FL. Am J Manag Care. 2012 Sep;18(7 Suppl):S176-82. Am J Manag Care. 2012. PMID: 23039866 Free article. Review.

2

Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial.

Poewe W, Seppi K, Fitzer-Attas CJ, Wenning GK, Gilman S, Low PA, Giladi N, Barone P, Sampaio C, Eyal E, Rascol O; Rasagiline-for-MSA investigators. Poewe W, et al. Lancet Neurol. 2015 Feb;14(2):145-52. doi: 10.1016/S1474-4422(14)70288-1. Epub 2014 Dec 8. Lancet Neurol. 2015. PMID: 25498732 Clinical Trial.

3

An update on the use of botulinum toxin therapy in Parkinson's disease.

Mills R, Bahroo L, Pagan F. Mills R, et al. Curr Neurol Neurosci Rep. 2015 Jan;15(1):511. doi: 10.1007/s11910-014-0511-3. Curr Neurol Neurosci Rep. 2015. PMID: 25407133 Review.

4

The Emerging Role of Pimavanserin in the Management of Parkinson's Disease Psychosis.

Hermanowicz N, Alva G, Pagan F, Espay AJ, Patel A, Madrid KC, Kremens D, Kenney J, Arquette S, Tereso G, Lopes M, Farnum C. Hermanowicz N, et al. J Manag Care Spec Pharm. 2017 Jun;23(6-b Suppl):S2-S8. doi: 10.18553/jmcp.2017.23.6-b.s2. J Manag Care Spec Pharm. 2017. PMID: 28636480 Free PMC article. Review.

5

Changing the treatment paradigm for Parkinson's disease psychosis with pimavanserin.

Lyons KE, Pahwa R, Hermanowicz N, Davis T, Pagan F, Isaacson S. Lyons KE, et al. Expert Rev Clin Pharmacol. 2019 Jul;12(7):681-691. doi: 10.1080/17512433.2019.1623669. Epub 2019 Jun 13. Expert Rev Clin Pharmacol. 2019. PMID: 31159608 Review.

6

A Pragmatic Approach to the Perioperative Management of Parkinson's Disease.

Lenka A, Mittal SO, Lamotte G, Pagan FL. Lenka A, et al. Among authors: pagan fl. Can J Neurol Sci. 2021 May;48(3):299-307. doi: 10.1017/cjn.2020.211. Epub 2020 Sep 22. Can J Neurol Sci. 2021. PMID: 32959743 Review.

7

Sialorrhea in Parkinson's Disease.

Isaacson J, Patel S, Torres-Yaghi Y, Pagán F. Isaacson J, et al. Toxins (Basel). 2020 Oct 31;12(11):691. doi: 10.3390/toxins12110691. Toxins (Basel). 2020. PMID: 33142833 Free PMC article. Review.

8

Long-Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease.

Pagan FL, Wilmarth B, Torres-Yaghi Y, Hebron ML, Mulki S, Ferrante D, Matar S, Ahn J, Moussa C. Pagan FL, et al. Mov Disord. 2021 Mar;36(3):740-749. doi: 10.1002/mds.28389. Epub 2020 Nov 20. Mov Disord. 2021. PMID: 33215762 Free PMC article. Clinical Trial.

9

Adenosine A_2A antagonists and Parkinson's disease.

Offit M, Nagle B, Ozay G, Zhang I, Kerasidis A, Torres-Yaghi Y, Pagan F. Offit M, et al. Int Rev Neurobiol. 2023;170:105-119. doi: 10.1016/bs.irn.2023.06.004. Epub 2023 Jul 3. Int Rev Neurobiol. 2023. PMID: 37741688

10

CXCR4 and CXCL12 expression is increased in the nigro-striatal system of Parkinson's disease.

Shimoji M, Pagan F, Healton EB, Mocchetti I. Shimoji M, et al. Neurotox Res. 2009 Oct;16(3):318-28. doi: 10.1007/s12640-009-9076-3. Epub 2009 Jun 24. Neurotox Res. 2009. PMID: 19551455

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

61 results

Search Page